Clinical Trials Logo

Clinical Trial Summary

The primary objective is to evaluate V114 in the prevention of vaccine-type acute otitis media (VT-AOM) and the safety of V114 with respect to the proportion of participants with serious adverse events (SAEs) through completion of the study. The primary hypothesis is that V114 is superior to no V114 in preventing VT-AOM as assessed by the incidence of VT-AOM.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04193215
Study type Interventional
Source Merck Sharp & Dohme LLC
Contact
Status Active, not recruiting
Phase Phase 3
Start date September 12, 2020
Completion date June 5, 2025